Everest Medicines Ltd
HKEX:1952
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
14.54
39.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Everest Medicines Ltd stock under the Base Case scenario is 30.72 HKD. Compared to the current market price of 37.7 HKD, Everest Medicines Ltd is Overvalued by 19%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Everest Medicines Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Everest Medicines Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Everest Medicines Ltd
Balance Sheet Decomposition
Everest Medicines Ltd
Current Assets | 2.3B |
Cash & Short-Term Investments | 1.9B |
Receivables | 293.6m |
Other Current Assets | 35.2m |
Non-Current Assets | 2.9B |
Long-Term Investments | 44.9m |
PP&E | 679.4m |
Intangibles | 2.2B |
Other Non-Current Assets | 8.1m |
Current Liabilities | 481.5m |
Accounts Payable | 70.3m |
Accrued Liabilities | 51.7m |
Other Current Liabilities | 359.6m |
Non-Current Liabilities | 284.2m |
Long-Term Debt | 278.3m |
Other Non-Current Liabilities | 6m |
Earnings Waterfall
Everest Medicines Ltd
Revenue
|
418.6m
CNY
|
Cost of Revenue
|
-101.5m
CNY
|
Gross Profit
|
317m
CNY
|
Operating Expenses
|
-1.1B
CNY
|
Operating Income
|
-750.8m
CNY
|
Other Expenses
|
-302.5m
CNY
|
Net Income
|
-1.1B
CNY
|
Free Cash Flow Analysis
Everest Medicines Ltd
CNY | |
Free Cash Flow | CNY |
In the first half of 2024, Everest Medicines reported a 158% increase in revenue, reaching RMB 301.5 million, driven by strong sales from XERAVA and the launch of Nefecon in May. The company's cash gross margin was 83%, maintaining operational efficiency while reducing operating expenses as a percentage of revenue by 29%. Everest achieved profitability at a commercial level for the first time and expects to meet their full-year revenue guidance of RMB 700 million. With RMB 1.93 billion in cash, they are well-positioned to continue their growth strategy, including advancing their mRNA therapeutic vaccine program.
What is Earnings Call?
Profitability Score
Profitability Due Diligence
Everest Medicines Ltd's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Everest Medicines Ltd's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Everest Medicines Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Everest Medicines Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Everest Medicines Ltd
According to Wall Street analysts, the average 1-year price target for Everest Medicines Ltd is 29.82 HKD with a low forecast of 24.75 HKD and a high forecast of 46.2 HKD.
Dividends
Current shareholder yield for Everest Medicines Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Everest Medicines Ltd. operates as a biopharmaceutical company which focuses on licensing, clinical development and commercialization of globally therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets. The company is headquartered in Shanghai, Shanghai and currently employs 405 full-time employees. The company went IPO on 2020-10-09. The firm is focusing on the research and development of innovative drug candidate. The firm built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The firm mainly provides its products and services in Greater China and other emerging Asia Pacific markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Everest Medicines Ltd stock under the Base Case scenario is 30.72 HKD.
Compared to the current market price of 37.7 HKD, Everest Medicines Ltd is Overvalued by 19%.